SG11202110406SA - Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole - Google Patents

Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole

Info

Publication number
SG11202110406SA
SG11202110406SA SG11202110406SA SG11202110406SA SG11202110406SA SG 11202110406S A SG11202110406S A SG 11202110406SA SG 11202110406S A SG11202110406S A SG 11202110406SA SG 11202110406S A SG11202110406S A SG 11202110406SA SG 11202110406S A SG11202110406S A SG 11202110406SA
Authority
SG
Singapore
Prior art keywords
pyrazole
thienyl
vinyl
solid forms
solid
Prior art date
Application number
SG11202110406SA
Inventor
An-Hu Li
Satish Kumar Sakilam
Dong Sung Lim
Original Assignee
Angion Biomedica Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angion Biomedica Corp filed Critical Angion Biomedica Corp
Publication of SG11202110406SA publication Critical patent/SG11202110406SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202110406SA 2019-04-11 2020-04-10 Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole SG11202110406SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832519P 2019-04-11 2019-04-11
PCT/US2020/027710 WO2020210657A1 (en) 2019-04-11 2020-04-10 Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole

Publications (1)

Publication Number Publication Date
SG11202110406SA true SG11202110406SA (en) 2021-10-28

Family

ID=72751396

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202110406SA SG11202110406SA (en) 2019-04-11 2020-04-10 Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole

Country Status (13)

Country Link
US (2) US10875849B2 (en)
EP (1) EP3927702A4 (en)
JP (1) JP2022526827A (en)
KR (1) KR20220004083A (en)
CN (1) CN114026085A (en)
AU (1) AU2020272036A1 (en)
BR (1) BR112021020367A2 (en)
CA (1) CA3133803A1 (en)
EA (1) EA202192786A1 (en)
IL (1) IL287118A (en)
MX (1) MX2021012250A (en)
SG (1) SG11202110406SA (en)
WO (1) WO2020210657A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020210657A1 (en) 2019-04-11 2020-10-15 Angion Biomedica Corp. Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole
WO2021087392A1 (en) * 2019-10-31 2021-05-06 Angion Biomedica Corp. Improving renal function after kidney transplantation
US11358963B2 (en) 2020-03-05 2022-06-14 Ankh Life Sciences Limited Low-temperature synthesis of thymoquinone and harmaline compounds
US20230372299A1 (en) * 2020-10-14 2023-11-23 Angion Biomedica Corp. Preparation of terevalefim and formulations thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE138770C (en)
JPS48713Y1 (en) 1967-12-19 1973-01-09
US4806535A (en) 1987-07-22 1989-02-21 Rorer Pharmaceutical Corporation Imidazolylphenyl and 1,2,4-triazolylphenyl benzopyridazinone and pyridopyridazinone compounds and their use for increasing cardiatonic contractility
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
JPH02193994A (en) 1989-01-23 1990-07-31 Kyowa Hakko Kogyo Co Ltd Pyridazinone derivative
US6566098B1 (en) 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
FR2669633B1 (en) 1990-11-23 1993-01-22 Adir NOVEL BENZOSELENAZOLINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
DE4405428A1 (en) 1993-07-05 1995-03-30 Bayer Ag 2-oximino-2-thienyl acetic acid derivatives
JP3680114B2 (en) 1993-09-17 2005-08-10 敏一 中村 Cranial nerve disorder treatment
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
JP3818322B2 (en) 1994-04-28 2006-09-06 敏一 中村 Collagen degradation promoter
CA2230819C (en) 1995-08-29 2009-04-14 Sumitomo Pharmaceuticals Co., Ltd. Medicament comprising hgf gene
US5830879A (en) 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
EP0935463B1 (en) 1996-10-31 2004-01-21 Harbor Branch Oceanographic Institution, Inc. Use of anti-neurogenic inflammatory compounds and compositions
JPH11288112A (en) 1998-04-06 1999-10-19 Mitsubishi Paper Mills Ltd Electrophotographic photoreceptor
US6677333B1 (en) 1999-01-26 2004-01-13 Ono Pharmaceutical Co., Ltd. 2H-phthalazin-1-one derivatives and drug containing its derivatives as active ingredient
PE20010306A1 (en) 1999-07-02 2001-03-29 Agouron Pharma INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE
US6437006B1 (en) 1999-09-27 2002-08-20 American Cyanamid Company Pharmaceutical carrier formulation
US7459536B1 (en) 1999-11-09 2008-12-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HGF-SF monoclonal antibody combinations
DK2236152T3 (en) 2000-04-12 2014-07-07 Novozymes Biopharma Dk As Albumin Fusion Proteins
CA2452445C (en) 2000-06-29 2011-02-15 North Shore-Long Island Jewish Health System Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
DE10047486A1 (en) 2000-09-26 2002-04-11 Bayer Ag Phenoxyphenyl alkanesulfonates
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US6589997B2 (en) 2001-06-29 2003-07-08 North Shore-Long Island Jewish Health System Small-molecule modulators of hepatocyte growth factor/scatter factor activities
US6610726B2 (en) 2001-06-29 2003-08-26 North Shore-Long Island Jewish Research Institute Compositions and agents for modulating cellular proliferation and angiogenesis
US20030073692A1 (en) 2001-08-07 2003-04-17 Pharmacia & Upjohn S.P.A. Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
DE10157184A1 (en) 2001-11-22 2003-07-17 Studiengesellschaft Kohle Mbh Process for the preparation of vinyl arenes, heteroarenes and 1,3-dienes from aryl or heteroaryl or. Vinyl carboxylic acid derivatives
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
AU2003213142B2 (en) 2002-02-22 2005-11-10 Merck Sharp & Dohme Llc Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
WO2004009599A1 (en) 2002-07-19 2004-01-29 Targacept, Inc. Five-membered heteroaromatic olefinic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of ncotinic cholinergic receptors
US7192976B2 (en) 2002-12-21 2007-03-20 Angion Biomedica Corporation Small molecule modulators of hepatocyte growth factor (scatter factor) activity
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
CA2579240A1 (en) 2004-09-28 2006-04-06 Angion Biomedica Corp. Small molecule modulators of cytokine activity
WO2006060654A2 (en) 2004-12-01 2006-06-08 Divergence, Inc. Pesticidal compositions and methods
WO2006078941A2 (en) 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Novel sirtuin activating compounds and methods of use thereof
US20110230407A1 (en) 2005-03-14 2011-09-22 Alexander Yuzhakov Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma
US7879898B1 (en) 2006-02-14 2011-02-01 Angion Biomedica Corp. Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease
KR20090035741A (en) * 2006-08-04 2009-04-10 엔싸이시브 파마슈티칼즈 인코퍼레이티드 Polymorph of N- (2-acetyl-4,6-dimethylphenyl) -3-) [(3,4-dimethyl-5-isoxazolyl) -amino] sulfonyl｝ -2-thiophene-carboxamide
SI2134691T1 (en) 2007-03-08 2012-06-29 Janssen Pharmaceutica Nv Quinolinone derivatives as parp and tank inhibitors
WO2009000673A2 (en) 2007-06-22 2008-12-31 Basf Se Light emitting cu(i) complexes
US8193177B2 (en) 2007-11-13 2012-06-05 Angion Biomedica Corp. Hepatocyte growth factor pathway activators in fibrotic connective tissue diseases
US8772326B2 (en) * 2008-07-10 2014-07-08 Anigion Biomedica Corp. Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
US20110098304A1 (en) 2008-10-22 2011-04-28 Bijoy Panicker Small molecule inhibitors of PARP activity
WO2010068287A2 (en) 2008-12-11 2010-06-17 Angion Biomedica Corp. Small molecule modulators of hepatocyte growth factor (scatter factor) activity
WO2011019400A2 (en) 2009-08-12 2011-02-17 Angion Biomedica Corp. Enhancement of cellular transplantation using small molecule modulators hepatocyte growth factor (scatter factor) activity
EP2550260A1 (en) 2010-03-24 2013-01-30 Medical University Of South Carolina Compositions and methods for the treatment of degenerative diseases
NZ700332A (en) 2010-03-30 2017-06-30 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
TWI492949B (en) * 2010-06-09 2015-07-21 Abbvie Bahamas Ltd Crystalline forms of kinase inhibitors
US20130190376A1 (en) * 2010-10-05 2013-07-25 David E. Smith Methods of use of small molecule modulators of hepatocyte growth factor (scatter factor) activity
WO2012058531A2 (en) 2010-10-29 2012-05-03 North Carolina State University Modulation of response regulators by imidazole derivatives
EP2804869B1 (en) * 2012-01-18 2019-06-12 Aurobindo Pharma Limited Novel solvates of darunavir
EP2757106A1 (en) 2013-01-21 2014-07-23 Saltigo GmbH Substituted benzimidazole phosphine compounds and a method for decarboxylating carbon-carbon bond
ES2853483T3 (en) 2013-03-15 2021-09-16 Verseon Int Corporation Multisubstituted aromatic compounds as serine protease inhibitors
JP6479749B2 (en) 2013-03-15 2019-03-06 ヴァーセオン コーポレイション Halogenopyrazoles as thrombin inhibitors
WO2020210657A1 (en) 2019-04-11 2020-10-15 Angion Biomedica Corp. Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole
WO2021087392A1 (en) * 2019-10-31 2021-05-06 Angion Biomedica Corp. Improving renal function after kidney transplantation

Also Published As

Publication number Publication date
EA202192786A1 (en) 2022-01-11
EP3927702A1 (en) 2021-12-29
IL287118A (en) 2021-12-01
WO2020210657A1 (en) 2020-10-15
US11370783B2 (en) 2022-06-28
US20200369654A1 (en) 2020-11-26
KR20220004083A (en) 2022-01-11
US20210078984A1 (en) 2021-03-18
US10875849B2 (en) 2020-12-29
CA3133803A1 (en) 2020-10-15
EP3927702A4 (en) 2022-05-11
BR112021020367A2 (en) 2021-12-07
AU2020272036A1 (en) 2021-11-04
JP2022526827A (en) 2022-05-26
CN114026085A (en) 2022-02-08
MX2021012250A (en) 2022-01-18

Similar Documents

Publication Publication Date Title
IL287118A (en) Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole
SG11202104206SA (en) New heterocyclic compounds
PT3814341T (en) Erbb receptor inhibitors
IL289617A (en) Heterocyclic compounds
IL289595A (en) Heterocyclic compounds
EP3395342A4 (en) TABLET COMPRISING 1- (3- (2- (1-BENZOTHIOPHEN-5-YL) ETHOXY) PROPYL) AZETIDIN-3-OL OR A SALT THEREOF
SG11202007013UA (en) Optimization of rate-of-penetration
IL288987A (en) New heterocyclic compounds
GB2558898B (en) Controlling transfer of data
IL272992A (en) Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
HK40065124A (en) Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole
GB201915191D0 (en) Novel heterocyclic compounds
GB2578453B8 (en) Software defined networks
GB201900370D0 (en) Resilent network routing
SG11202110151TA (en) Inter-core network reselection control
GB201803398D0 (en) Methods for controlling gene expression
GB201806488D0 (en) Heterocyclic TADF compounds
HK40115548A (en) Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
HK40114639A (en) Erbb receptor inhibitors
IL284752A (en) Peripheral CB1 receptor inhibitors
CA196729S (en) Horseshoe
CA194058S (en) Jacket
CA194059S (en) Jacket
EP3980406A4 (en) Heterocyclic compounds
HK40079682A (en) Novel heterocyclic compounds